"We received permission to conduct clinical trials on December 30. All pre-clinical trials are over. Clinical trials began soon after the New Year. However, since it is a new molecule - it’s patented and unparalleled - we are conducting phase one trials particularly carefully because we need to prove that it’s safe for humans. We will complete phase one by mid-March. We are about to start working with patients and launch phase two," she said.
More about: Russia coronavirus